Product Description
IGM-7354 is a targeted IL-15 immune stimulating antibody for the treatment of patients with solid and hematologic malignancies. The antibody binding domains of IGM-7354 target PD-L1 on the surface of cells such as cancer cells, to selectively deliver IL-15 in the region of those PD-L1 expressing cells. We believe IGM-7354 may be able to enhance the immune system’s activity in the tumor microenvironment and may also potentially reduce toxicities of this type of therapy in other regions of the body. (Sourced from: https://igmbio.com/pipeline/igm-7354/)
Mechanisms of Action: IL15 Inhibitor,PD-L1 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| IGM-7354-001 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2024-05-31 |
12% |
2024-07-25 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/05/2023 |
News Article |
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension |
|
04/13/2023 |
News Article |
IGM Biosciences Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023 |
|
01/17/2023 |
News Article |
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors |